Toader Corneliu, Serban Matei, Munteanu Octavian, Covache-Busuioc Razvan-Adrian, Enyedi Mihaly, Ciurea Alexandru Vlad, Tataru Calin Petru
Department of Neurosurgery, "Carol Davila" University of Medicine and Pharmacy, 020021 Bucharest, Romania.
Department of Vascular Neurosurgery, National Institute of Neurology and Neurovascular Diseases, 077160 Bucharest, Romania.
Int J Mol Sci. 2025 Apr 30;26(9):4271. doi: 10.3390/ijms26094271.
The brain-derived neurotrophic factor (BDNF) has become one of the cornerstones of neuropathology, influencing synaptic plasticity, cognitive resilience, and neuronal survival. Apart from its molecular biology, BDNF is a powerful target for transformative benefit in precision medicine, leading to innovative therapeutic approaches for neurodegenerative and psychiatric diseases like Alzheimer's disease (AD), Parkinson's disease (PD), major depressive disorder (MDD), and post-traumatic stress disorder (PTSD). Nevertheless, clinical applicability is obstructed by hurdles in delivery, patient-specific diversity, and pleiotropic signaling. Here, we summarize findings in BDNF research, including its regulatory pathways and diagnostic/prognostic biomarkers and integrative therapeutic approaches. We describe innovative delivery systems, such as lipid nanoparticle-based mRNA therapies and CRISPR-dCas9-based epigenetic editing that bypass obstacles such as BBB (blood-brain barrier) and enzymatic degradation. The recent implementation of multiplex panels combining BDNF biodynamic indicators with tau and amyloid-β signaling markers showcases novel levels of specificity for both early detection and potential therapeutic monitoring. Humanized preclinical models like iPSC-derived neurons and organoids point to the key role of BDNF in neurodeveloping and neurodegenerative processes, paralleling advances in bridging preclinical observation and clinical environments. Moreover, novel therapeutic tools delivering TrkB activators or the implementation of AI-based dynamic care platforms enable tailored and scalable treatments. This review also aims to extend a framework used in the understanding of BDNF's relevance to traditional neurodegenerative models by situating more recent work detailing BDNF's actions in ischemic tissues and the gut-brain axis in the context of systemic health. Finally, we outline a roadmap for the incorporation of BDNF-centered therapies into worldwide healthcare, highlighting ethical issues, equity, and interdisciplinary decomposition. The therapeutic potential of BDNF heralds a new era in neuroscience and medicine, revolutionizing brain health and paving the way for the advancement of precision medicine.
脑源性神经营养因子(BDNF)已成为神经病理学的基石之一,影响突触可塑性、认知恢复力和神经元存活。除了其分子生物学外,BDNF还是精准医学中实现变革性益处的有力靶点,催生了针对阿尔茨海默病(AD)、帕金森病(PD)、重度抑郁症(MDD)和创伤后应激障碍(PTSD)等神经退行性疾病和精神疾病的创新治疗方法。然而,临床应用受到给药障碍、患者特异性差异和多效性信号传导的阻碍。在这里,我们总结了BDNF研究的结果,包括其调节途径、诊断/预后生物标志物和综合治疗方法。我们描述了创新的给药系统,如基于脂质纳米颗粒的mRNA疗法和基于CRISPR-dCas9的表观遗传编辑,这些系统绕过了血脑屏障(BBB)和酶降解等障碍。最近将BDNF生物动力学指标与tau和淀粉样β信号标记物相结合的多重检测面板展示了早期检测和潜在治疗监测的新特异性水平。像诱导多能干细胞衍生的神经元和类器官这样的人源化临床前模型指出了BDNF在神经发育和神经退行性过程中的关键作用,这与弥合临床前观察和临床环境之间差距的进展并行。此外,提供TrkB激活剂的新型治疗工具或基于人工智能的动态护理平台的实施实现了定制化和可扩展的治疗。本综述还旨在通过将最近详细描述BDNF在缺血组织和肠脑轴中的作用的工作置于全身健康的背景下,扩展用于理解BDNF与传统神经退行性模型相关性的框架。最后,我们概述了将以BDNF为中心的疗法纳入全球医疗保健的路线图,强调了伦理问题、公平性和跨学科分解。BDNF的治疗潜力预示着神经科学和医学的新时代,彻底改变脑健康并为精准医学的进步铺平道路。